Inhalation Sciences signs IRS contract worth 491,000 SEK with returning nanotechnology client
A leading nanotechnology company has returned to carry out another research project with Inhalation Research Services (IRS), ISAB’s contract research organization. The previous project, worth 584,000 SEK, began in February 2022. The new project, worth 491,000 SEK, will test slightly different versions of the company’s porous inhalable nanoparticles. Further studies with the same client are planned for later in 2022.
A leading company in the field of nanoparticle drug delivery has returned to IRS to initiate a new research project following a successful collaboration earlier in the year. The client company is exploring the development of inhalable porous nanoporous particles for drug delivery.
The client chose to use ISAB’s intratracheal in vivo exposure module in its original project, a unique method that uses individual test rodents, unlike the ‘towers’ of multiple test rodents used in much conventional testing. It bypasses the animal’s nose and gently delivers aerosol directly to the lungs whilst carefully monitoring aerosol concentration and breathing patterns. The data generated is exceptionally precise and voluminous, evaluating how test particles dissolve in the lung, and how quickly they move into the bloodstream.
ISAB CEO Manoush Masarrat: “This client clearly appreciates the accuracy of the results we deliver and the difference we can make for them and their clients. We’re pleased to work again with a company of this stature and look forward to continuing the collaboration.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on April 1, 2022.
Tags: